By Dr. Chinta SidharthanMar 18 2024Reviewed by Lily Ramsey, LLM In a recent study published in The New England Journal of Medicine, a team of scientists from the United States and Canada evaluated the performance of a blood-based testing method that uses cell-free deoxyribonucleic acid to screen for colorectal cancer.
Individuals in whom the cancer is detected early, in the localized stages, have a 91% five-year survival rate, while those in whom the cancer has moved to the metastatic stage have a 14% five-year survival rate. About the study In the present study, the scientists evaluated the performance of a blood-based test that screens for colorectal cancer using cell-free DNA.
Individuals with inflammatory bowel disease, a genetic predisposition to or family history of colorectal cancer, or any history of cancer were excluded from the study. The two primary outcomes of the study were the sensitivity and specificity for colorectal cancer and advanced neoplasia, respectively. The test's sensitivity in detecting advanced precancerous lesions was the secondary outcome.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: medical_xpress - 🏆 101. / 51 Read more »
Source: NewsMedical - 🏆 19. / 71 Read more »